CD141 Monoclonal Antibody (LS17-9), eBioscience™, Invitrogen™

Description

• The MAb LS17-9 recognizes mouse CD141 (Thrombomodulin, BDCA-3), a type I cell surface glycoprotein that binds to and allosterically activates thrombin
• This complex cleaves protein C and the Thrombin Activatable Fibrinolysis Inhibitor (TAFI), initiating an important anticoagulant and antifibrinolytic pathway
• Although expressed across many tissues and cell types, its highest expression has been reported on the lumenal surface of vascular endothelial cell
• In the immune system the highest expression can be observed on monocytes and macrophages
• Soluble CD141 is constitutively present in the serum at a very low level, and can be upregulated during inflammation
• The anti-inflammatory activity of CD141 results from its ability to block the highly pro-inflammatory activity of thrombin
• CD141 prevents chemotaxis and binding of granulocytes to activated endothelium, and inhibits activation of eosinophils and mast cells thereby reducing inflammation
• Although human CD141 is commonly used as a marker of cross-presenting dendritic cells, mouse CD141 does not exhibit the same expression pattern
• Thrombomodulin (TM) is also known as Fetomodulin (FM), endothelial anticoagulant protein, or glycoprotein P112
• Thrombomodulin contains six repeated domains homologous with epidermal growth factor (EGF) and an amino terminal domain homologous to lectin-like protein
• Through its accelerated activation of protein C, synthesis of TM is one of several mechanisms important in maintaining thrombo-resistance and thus reducing clot formation on the surface of the endothelial cells
• Immunohistochemical staining of formalin-fixed tissue for TM has been used for the study of a variety of vascular tumors, meningiomas and choriocarcinomas.